Craft

Cogent Biosciences

Stock Price

$7.5

2024-05-03

Market Capitalization

$720 M

2024-05-03

Cogent Biosciences Summary

Company Summary

Overview
Cogent Biosciences (formerly known as Unum Therapeutics) is a biotechnology company that designs precision therapies to treat genetically driven diseases. It offers bezuclastinib, a tyrosine kinase type III (KIT) inhibitor designed to target exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. The company also provides Phase 2 clinical trial Apex that evaluates pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Type
Public
Status
Active
Founded
2014
HQ
Waltham, MA, US | view all locations
Website
https://www.cogentbio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Andrew Robbins

    Andrew Robbins, Chief Executive Officer and President

  • John Green

    John Green, Chief Financial Officer

  • Brad Barnett

    Brad Barnett, Chief Technology Officer

  • John Robinson

    John Robinson, Chief Scientific Officer

LocationsView all

2 locations detected

  • Waltham, MA HQ

    United States

    275 Wyman St 3rd floor

  • Boulder, CO

    United States

    4840 Pearl E Cir # 100

Cogent Biosciences Financials

Summary Financials

Net income (FY, 2023)
($192.4M)
Cash (Q1, 2024)
$215.8M
EBIT (FY, 2023)
($208.1M)
Enterprise value
$544.7M

Footer menu